Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hetrazepine PAF antagonists.

K Ikegami1, C J Meade, H O Heuer

  • 1Nippon Boehringer Ingelheim, Kawanishi, Japan.

Journal of Lipid Mediators
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breakthrough instruments and products steady-state and time-resolved photoluminescence using the FluoTime 300 spectrometer with a FluoMic add-on.

The Review of scientific instruments·2020
Same author

Enhancement of the luteinising hormone surge by male olfactory signals is associated with anteroventral periventricular Kiss1 cell activation in female rats.

Journal of neuroendocrinology·2017
Same author

Evidence of involvement of neurone-glia/neurone-neurone communications via gap junctions in synchronised activity of KNDy neurones.

Journal of neuroendocrinology·2017
Same author

Neonatal Kisspeptin is Steroid-Independently Required for Defeminisation and Peripubertal Kisspeptin-Induced Testosterone is Required for Masculinisation of the Brain: A Behavioural Study Using Kiss1 Knockout Rats.

Journal of neuroendocrinology·2016
Same author

Numerical study of plasma generation process and internal antenna heat loadings in J-PARC RF negative ion source.

The Review of scientific instruments·2016
Same author

Pre-conditioning procedure suitable for internal-RF-antenna of J-PARC RF-driven H⁻ ion source.

The Review of scientific instruments·2016
Same journal

Cytosolic PLA2: mRNA levels and potential for transcriptional regulation.

Journal of lipid mediators·1993
Same journal

Phospholipase D-mediated hydrolysis of phosphatidylcholine: role in cell signalling.

Journal of lipid mediators·1993
Same journal

Sphingosine and sphingosine 1-phosphate in cellular proliferation: relationship with protein kinase C and phosphatidic acid.

Journal of lipid mediators·1993
Same journal

Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes.

Journal of lipid mediators·1993
Same journal

PAF-releasing factor in human serum and inflammatory exudate.

Journal of lipid mediators·1993
Same journal

5-Lipoxygenase activity in the human pancreas.

Journal of lipid mediators·1993
See all related articles

Hetrazepines are potent platelet-activating factor (PAF) antagonists that do not cause sedation. These compounds may target both cell-surface and intracellular PAF receptors, explaining their therapeutic potential in inflammatory diseases.

Area of Science:

  • Pharmacology
  • Immunology
  • Molecular Biology

Background:

  • Platelet-activating factor (PAF) is a key mediator in inflammatory and allergic responses.
  • Hetrazepines are structurally similar to hypnotic drugs but lack sedative effects.
  • Understanding the receptor interactions of hetrazepines is crucial for their therapeutic application.

Purpose of the Study:

  • To investigate the pharmacological profile of hetrazepines as PAF antagonists.
  • To explore the binding sites and potential therapeutic mechanisms of hetrazepines.
  • To elucidate the lack of hypnotic action despite structural similarities to sedatives.

Main Methods:

  • Competitive binding assays to determine PAF receptor antagonism.
  • In vitro and in vivo disease models to assess therapeutic efficacy.

Related Experiment Videos

  • Pharmacological characterization of hetrazepine interactions with PAF receptors.

    • Main Results:

    • Hetrazepines (WEB-2086, WEB-2170) demonstrated potent, specific, and competitive antagonism of PAF.
    • These antagonists bind to the same site as PAF on cell-surface receptors.
    • Evidence suggests binding to intracellular PAF receptors, differentiating them from classical hypnotics.
    • Hetrazepines showed efficacy in disease models involving neutrophil adherence.

    Conclusions:

    • Hetrazepines are effective PAF antagonists with a unique dual receptor binding profile.
    • Their lack of hypnotic effects is likely due to their specific PAF receptor interactions.
    • Targeting both cell-surface and intracellular PAF receptors offers a novel therapeutic strategy for inflammatory conditions.